INAB Stock Analysis: Buy, Sell, or Hold?
INAB - IN8bio, Inc. Common Stock
$1.34
0.01 (0.75%)
▲
5d:
-6.94%
30d:
-4.29%
90d:
-3.6%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When INAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called INAB this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INAB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INAB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INAB is currently trading at $1.34, which is considered oversold relative to its 30-day fair value range of $1.37 to $1.45.
Technical Outlook: Technically, INAB is in a downtrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INAB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.25 (+366.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INAB is in a downtrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INAB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.25 (+366.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.37 -
$1.45
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 366.4% below Wall St target ($6.25)
- CAUTION: 5-day price weakness (-6.9%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.37 -
$1.45
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.40
Resistance Level
$1.88
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.26
Wall Street Target
$6.25
(+366.4%)
Share & Embed Analysis
Last updated: July 14, 2026 7:15 AM ET
Data refreshes hourly during market hours. Next update: 8:15 AM
Data refreshes hourly during market hours. Next update: 8:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
